The chemical class of GPR89C Inhibitors includes compounds that modulate the activity of the GPR89C protein through various indirect mechanisms. These compounds operate through diverse pathways, influencing different cellular processes and signaling pathways related to GPR89C's function.
Compounds like Sodium butyrate and Forskolin, known for their roles in histone deacetylation and adenylyl cyclase activation respectively, might influence the transcriptional regulation and cAMP-mediated signaling of GPR89C. Similarly, PD98059 and LY294002, which target MEK and PI3K pathways, respectively, could affect GPR89C's function in cell signaling and survival.
Furthermore, Rapamycin's role in mTOR inhibition and SB203580's influence on p38 MAP kinase pathways highlight the complex interactions in cellular growth and stress response mechanisms that can affect GPR89C. U0126 and Wnt Inhibitor I further illustrate the modulation of ERK and Wnt/β-catenin signaling pathways, respectively, in relation to GPR89C.
Additionally, Sunitinib and Bafilomycin A1, through their roles in angiogenesis and vesicular transport, demonstrate the breadth of cellular processes that can intersect with GPR89C's activity. JNK Inhibitor II and DAPT, targeting c-Jun N-terminal kinase and γ-secretase respectively, underscore the diverse regulatory pathways that can be leveraged to modulate GPR89C.
In summary, the chemical class of GPR89C Inhibitors represents a diverse array of compounds with varied molecular actions. These inhibitors, through their interactions with different cellular pathways, offer multiple strategies for modulating the activity of GPR89C. Understanding these diverse mechanisms is crucial for comprehending the multifaceted nature of protein regulation and opens up avenues for research into the modulation of specific proteins like GPR89C.
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 18 | |
Histone deacetylase inhibitor, may affect gene expression including genes related to GPR89C function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Adenylyl cyclase activator, potentially altering cAMP levels and influencing GPR89C-related signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor, could modulate MAPK/ERK pathway potentially intersecting with GPR89C function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor, possibly affecting GPR89C through the PI3K/Akt pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, could impact cellular processes related to GPR89C through mTOR pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAP kinase inhibitor, may modulate stress-activated protein kinase pathways affecting GPR89C. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor, could impact ERK signaling pathways related to GPR89C activity. | ||||||
Wnt Agonist | 853220-52-7 | sc-222416 sc-222416A | 5 mg 25 mg | $154.00 $597.00 | 23 | |
Inhibits Wnt/β-catenin pathway, could influence GPR89C related to cell signaling and development. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Tyrosine kinase inhibitor, potentially affecting angiogenesis pathways related to GPR89C. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
V-ATPase inhibitor, could influence vesicular transport pathways intersecting with GPR89C function. |